<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01042548</url>
  </required_header>
  <id_info>
    <org_study_id>09-028</org_study_id>
    <nct_id>NCT01042548</nct_id>
  </id_info>
  <brief_title>Proteomics and Radiomics Research of Breast Cancer Markers in Tissue, Interstitial Fluid and Serum</brief_title>
  <official_title>Proteomics and Radiomics Research of Breast Cancer Markers in Tissue, Interstitial Fluid and Serum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>David Scaife Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study is a case control study involving comparisons of tissue interstitial fluid&#xD;
      from breast cancer and adjacent non-cancerous tissue as well as that from benign breast&#xD;
      lesion and its adjacent non-diseased tissue for a distinguishable breast cancer profile. The&#xD;
      purpose of this research is to collect fresh breast nodule/cancer and surrounding&#xD;
      non-cancerous tissue for proteomic studies of the interstitial fluid to identify a profile&#xD;
      distinguishing breast cancer which will also permit future research on stored interstitial&#xD;
      fluid, blood or tissue samples. Specific markers identified from interstitial fluid study&#xD;
      will be investigated in blood samples to develop serum markers for breast cancer diagnosis&#xD;
      and prognosis. Additionally, we will perform both prospective and retrospective research on&#xD;
      breast cancer involving clinical, demographic, epidemiologic information, treatment,&#xD;
      follow-up and outcomes on breast nodule/cancer cases collected.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 3, 2010</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Breast Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Subjects will be asked to allow us to collect an extra 2 tablespoons of blood at the time of&#xD;
      pre-operative blood work. For those subjects with cancer who undergo surgery, a follow-up&#xD;
      blood sample will be collected prior to chemotherapy, radiation, or hormonal therapy, and&#xD;
      every six months afterwards at the time of their standard clinic/office visit for two years,&#xD;
      then once a year for year 3-5. This will allow researchers to examine the samples to&#xD;
      determine if blood changes over time after surgery, and what type of result may indicate a&#xD;
      risk for recurrence.&#xD;
&#xD;
      Any remaining blood samples not used for the study will remain in the laboratory for future&#xD;
      research.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients who are receiving or seeking medical care at the UPMC St. Margaret for breast&#xD;
        cancer will be invited to participate in the research study. Patients undergoing surgery&#xD;
        for breast nodules suspected of being cancer or high risk lesions will also be asked to&#xD;
        participate.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All subjects â‰¥ 18 years of age undergoing surgery for indeterminate breast nodules and&#xD;
             all subjects with newly diagnosed breast cancer will be eligible to participate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anyone &lt; 18 years of age.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laura Chiesa</last_name>
    <phone>412-831-1320</phone>
    <email>powersl2@upmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Min Sun, MD, PhD</last_name>
    <phone>412-781-3744</phone>
    <email>sunxmx@UPMC.EDU</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UPMC St. Margaret</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Chiesa</last_name>
      <phone>412-831-1320</phone>
      <email>powersl2@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Min Sun, MD, PhD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Min Sun, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 4, 2010</study_first_submitted>
  <study_first_submitted_qc>January 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2010</study_first_posted>
  <last_update_submitted>April 20, 2021</last_update_submitted>
  <last_update_submitted_qc>April 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Min Sun</investigator_full_name>
    <investigator_title>MD, PD</investigator_title>
  </responsible_party>
  <keyword>Proteomics</keyword>
  <keyword>Breast Cancer Markers</keyword>
  <keyword>Tissue Interstitial Fluid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

